ClinicalTrials.gg
CompletedNCT03334539VELOS-1Updated Mar 7, 2024Results posted

A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes

A Phase 2 interventional study of HL036 ophthalmic solution and Placebo vehicle solution in Dry Eye, sponsored by HanAll BioPharma Co., Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by HanAll BioPharma Co., Ltd. (part of Daewoong Pharmaceutical Co. LTD.) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
139th of 473
150 · median 60
Started
2017
with 15 others
Phase 2
97 of 544
5 open now
Registered
249th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 139th largest by enrollment of the 473 interventional ones that give a count, is one of 16 that started in 2017, is one of 97 in phase 2, and was the 249th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a patient-reported history of dry eye for at least 6 months prior to enrollment
  • Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1
  • Have in the study eye a Schirmer's Test score of ≤ 10 mm and ≥ 1 mm at Visits 1 and 2

Exclusion criteria

Exclusion Criteria:

  • Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1
  • Have used Restasis® or Xiidra® within 60 days of Visit 1
  • Be currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter (OTC) solutions, artificial tears, gels or scrubs, and cannot discontinue these medications for the duration of the trial (excluding medications allowed for the conduct of the study)
  • Have an uncontrolled systemic disease
  • Be a woman who is pregnant, nursing or planning a pregnancy
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    0.10% HL036 Ophthalmic Solution

    Participants self-administered HL036 0.10 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment® (CAE) were conducted at Day 1, Day 15, Day 29 and Day 57.

    Biological: HL036 ophthalmic solution

  • Experimental
    0.25% HL036 Ophthalmic Solution

    Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.

    Biological: HL036 ophthalmic solution

  • Placebo comparator
    Placebo

    Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.

    Other: Placebo vehicle solution

Interventions

  • BiologicalTanfanerceptStudies of TanfanerceptTanfanercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    HL036 ophthalmic solution

    Also known as: Tanfanercept

  • OtherPlacebo vehicle solution

    Placebo vehicle solution

06

What researchers measure

Primary outcomes

  1. Coprimary Endpoint: Change From Baseline in Inferior Corneal Staining Score to Day 57 (Pre-CAE)

    It was evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement.

    Time frame: Baseline (Day 1 Pre-CAE), Day 57 (Pre-CAE)

  2. Coprimary Endpoint: Change From Baseline in Ocular Discomfort Score to Day 57 (Pre-CAE)

    It is assessed by the Ora Calibra® Ocular Discomfort scale. The score ranged from 0 to 4 (0=none and 4=severe) with 1 point increments, where lower scores indicate improvement.

    Time frame: Baseline (Day 1 Pre-CAE), Day 57 (Pre-CAE)

Secondary outcomes

  1. Mean Change From Baseline in Fluorescein Staining (Inferior Region)

    It is evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  2. Mean Change From Baseline in Fluorescein Staining (Superior Region)

    It is evaluated for the superior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  3. Mean Change From Baseline in Fluorescein Staining (Central Region)

    It is evaluated for the central region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  4. Mean Change From Baseline in Fluorescein Staining (Temporal Region)

    It is evaluated for the temporal region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  5. Mean Change From Baseline in Fluorescein Staining (Nasal Region)

    It is evaluated for the nasal region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  6. Mean Change From Baseline in Fluorescein Staining (Corneal Sum)

    Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Corneal sum score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  7. Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)

    Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Conjunctival sum score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  8. Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)

    Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  9. Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)

    It is evaluated for the inferior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  10. Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)

    It is evaluated for the superior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  11. Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)

    It is evaluated for the central region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  12. Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)

    It is evaluated for the temporal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  13. Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)

    It is evaluated for the nasal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  14. Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)

    Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  15. Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)

    Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  16. Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)

    Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  17. Change From Baseline in Tear Film Break-Up Time

    Sodium fluorescein solution was instilled into each eye and participants were instructed to blinked several times. The time it takes to form micelles from the time that the eye is opened was noted.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  18. Change From Baseline in the Ora Calibra® Conjunctival Redness Scale

    It is evaluated by the Ora Calibra® conjunctival redness scale for dry eye. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  19. Change From Baseline in Schirmer's Test

    The Schirmer test strip will be placed in the lower temporal lid margin of each eye. Subjects will be instructed to close their eyes and After 5 minutes have elapsed, The length of moistened area of schirmer strip will be recorded (mm) for each eye.

    Time frame: Baseline (Day 1); Days 15, 29, and 57

  20. Change From Baseline in Ora Calibra® Ocular Discomfort Scale

    It was assessed by the Ora Calibra® ocular discomfort scale. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  21. Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)

    Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of overall ocular discomfort at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  22. Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)

    Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of burning at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  23. Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)

    Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of dryness at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  24. Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)

    Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of grittiness at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  25. Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)

    Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of stinging at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  26. Change From Baseline in Visual Analog Scale (Burning)

    Participants rated ocular symptom of burning by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  27. Change From Baseline in Visual Analog Scale (Itching)

    Participants rated ocular symptom of itching by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  28. Change From Baseline in Visual Analog Scale (Foreign Body)

    Participants rated ocular symptom of foreign body by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  29. Change From Baseline in Visual Analog Scale (Blurred Vision)

    Participants rated ocular symptom of blurred vision by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  30. Change From Baseline in Visual Analog Scale (Dryness)

    Participants rated ocular symptom of dryness by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  31. Change From Baseline in Visual Analog Scale (Photophobia)

    Participants rated ocular symptom of photophobia by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  32. Change From Baseline in Visual Analog Scale (Pain)

    Participants rated ocular symptom of pain by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

    Time frame: Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)

  33. Change From Baseline in Ocular Surface and Disease Index (OSDI©)

    The OSDI is a simple 12-question survey that rates the severity of the participant's dry eye disease based on the symptoms. It is assessed on a scale of 0 to 100, with higher score representing greater disability.

    Time frame: Baseline (Day 1); Days 8, 15, 29, and 57

  34. Ora Calibra® Drop Comfort Scale

    Ora Calibra® drop comfort scale ranges from 0 to 10. A score of 0 indicates comfortable and 10 indicates uncomfortable. Lower score indicated better comfort level.

    Time frame: Upon instillation and 1 and 2 minutes post-instillation on Day 1

  35. Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)

    Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of overall ocular discomfort twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

    Time frame: From Baseline (Day 1) to Day 56

  36. Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)

    Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of burning twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

    Time frame: From Baseline (Day 1) to Day 56

  37. Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)

    Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of dryness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

    Time frame: From Baseline (Day 1) to Day 56

  38. Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)

    Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of grittiness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

    Time frame: From Baseline (Day 1) to Day 56

  39. Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)

    Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of stinging twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

    Time frame: From Baseline (Day 1) to Day 56

07

Results

Posted Jan 26, 2022

Participant flow

Participants who met all the eligibility criteria were enrolled at 2 sites in the United States.

Participant flow — Overall Study
Milestone0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Started505050
Completed464349
Not completed471
Withdrew: Adverse event350
Withdrew: Withdrawal by subject011
Withdrew: Administrative reasons100
Withdrew: Hypertension not controlled010

Outcome measures

PrimaryCoprimary Endpoint: Change From Baseline in Inferior Corneal Staining Score to Day 57 (Pre-CAE)

It was evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement.

Time frame:
Baseline (Day 1 Pre-CAE), Day 57 (Pre-CAE)
Reported as:
Mean · score on a scale
Coprimary Endpoint: Change From Baseline in Inferior Corneal Staining Score to Day 57 (Pre-CAE)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE1.94 ± 0.5121.96 ± 0.4501.95 ± 0.433
Change From Baseline to Day 57 (pre-CAE)0.10 ± 0.6990.10 ± 0.490-0.02 ± 0.631
Statistical analysis
  • 0.10% HL036 Ophthalmic Solution vs Placebo · ANCOVA · p = 0.3378 (P-value was calculated using a model with treatment, baseline score, and site as covariates.) · Least squares (ls) mean difference: 0.11 · 95% CI -0.12 to 0.34
  • 0.25% HL036 Ophthalmic Solution vs Placebo · ANCOVA · p = 0.2883 (P-value was calculated using a model with treatment, baseline score, and site as covariates.) · Ls mean difference: 0.12 · 95% CI -0.10 to 0.35
  • 0.10% HL036 Ophthalmic Solution vs 0.25% HL036 Ophthalmic Solution · ANCOVA · p = 0.9293 (P-value calculated using a model with treatment, baseline score, and site as covariates) · Ls mean difference: 0.01 · 95% CI -0.22 to 0.24
PrimaryCoprimary Endpoint: Change From Baseline in Ocular Discomfort Score to Day 57 (Pre-CAE)

It is assessed by the Ora Calibra® Ocular Discomfort scale. The score ranged from 0 to 4 (0=none and 4=severe) with 1 point increments, where lower scores indicate improvement.

Time frame:
Baseline (Day 1 Pre-CAE), Day 57 (Pre-CAE)
Reported as:
Mean · score on a scale
Coprimary Endpoint: Change From Baseline in Ocular Discomfort Score to Day 57 (Pre-CAE)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE2.6 ± 0.862.5 ± 0.952.4 ± 0.75
Change from Baseline: Day 57 (Pre-CAE)-0.5 ± 1.16-0.4 ± 1.33-0.1 ± 0.88
Statistical analysis
  • 0.10% HL036 Ophthalmic Solution vs Placebo · ANCOVA · p = 0.1473 (P-value calculated using a model with treatment, baseline score, and site as covariates.) · Ls mean difference: -0.3 · 95% CI -0.7 to 0.1
  • 0.25% HL036 Ophthalmic Solution vs Placebo · ANCOVA · p = 0.2321 (P-value calculated using a model with treatment, baseline score, and site as covariates.) · Ls mean difference: -0.3 · 95% CI -0.7 to 0.2
  • 0.10% HL036 Ophthalmic Solution vs 0.25% HL036 Ophthalmic Solution · ANCOVA · p = 0.8217 (P-value calculated using a model with treatment, baseline score, and site as covariates.) · Ls mean difference: 0.0 · 95% CI -0.4 to 0.5
SecondaryMean Change From Baseline in Fluorescein Staining (Inferior Region)

It is evaluated for the inferior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Fluorescein Staining (Inferior Region)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE1.94 ± 0.5121.96 ± 0.4501.95 ± 0.443
Day 1 Post-CAE3.32 ± 0.4923.25 ± 0.5653.20 ± 0.474
Day 1 (Change from Pre-CAE to Post-CAE)1.38 ± 0.5211.29 ± 0.4641.25 ± 0.407
Change from Baseline: Day 80.19 ± 0.706-0.01 ± 0.6060.04 ± 0.668
Change from Baseline: Day 15 (Pre-CAE)-0.12 ± 0.697-0.20 ± 0.608-0.10 ± 0.571
Change from Baseline: Day 15 (Post-CAE)-0.62 ± 0.766-0.85 ± 0.736-0.69 ± 0.826
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.50 ± 0.892-0.66 ± 0.793-0.59 ± 0.867
Change from Baseline: Day 29 (Pre-CAE)0.04 ± 0.8070.04 ± 0.5630.00 ± 0.707
Change from Baseline: Day 29 (Post-CAE)-0.41 ± 0.656-0.83 ± 0.677-0.48 ± 0.569
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.66 ± 0.857-1.02 ± 0.624-0.64 ± 0.591
Change from Baseline: Day 57 (Pre-CAE)0.12 ± 0.7240.10 ± 0.512-0.02 ± 0.631
Change from Baseline: Day 57 (Post-CAE)-0.47 ± 0.670-0.84 ± 0.738-0.63 ± 0.610
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.59 ± 0.878-0.92 ± 0.663-0.62 ± 0.747
SecondaryMean Change From Baseline in Fluorescein Staining (Superior Region)

It is evaluated for the superior region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Fluorescein Staining (Superior Region)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE2.05 ± 0.4202.08 ± 0.4442.03 ± 0.456
Day 1 Post-CAE2.69 ± 0.5522.56 ± 0.5592.45 ± 0.556
Day 1 (Change from Pre-CAE to Post-CAE)0.64 ± 0.5980.48 ± 0.6220.42 ± 0.650
Change from Baseline: Day 8-0.09 ± 0.586-0.27 ± 0.592-0.09 ± 0.556
Change from Baseline: Day 15 (Pre-CAE)-0.22 ± 0.790-0.45 ± 0.724-0.29 ± 0.615
Change from Baseline: Day 15 (Post-CAE)-0.66 ± 0.976-0.72 ± 0.798-0.34 ± 0.658
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.44 ± 0.884-0.27 ± 0.743-0.05 ± 0.791
Change from Baseline: Day 29 (Pre-CAE)-0.27 ± 0.709-0.25 ± 0.555-0.10 ± 0.707
Change from Baseline: Day 29 (Post-CAE)-0.50 ± 0.655-0.65 ± 0.822-0.07 ± 0.604
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.41 ± 0.791-0.52 ± 0.964-0.09 ± 0.782
Change from Baseline: Day 57 (Pre-CAE)-0.09 ± 0.571-0.14 ± 0.594-0.19 ± 0.713
Change from Baseline: Day 57 (Post-CAE)-0.46 ± 0.665-0.37 ± 0.787-0.23 ± 0.662
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.37 ± 0.806-0.21 ± 0.847-0.08 ± 0.915
SecondaryMean Change From Baseline in Fluorescein Staining (Central Region)

It is evaluated for the central region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Fluorescein Staining (Central Region)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE1.45 ± 0.6871.57 ± 0.6701.49 ± 0.610
Day 1 Post-CAE2.22 ± 0.6242.09 ± 0.5502.04 ± 0.676
Day 1 (Change from Pre-CAE to Post-CAE)0.77 ± 0.6410.052 ± 0.7350.55 ± 0.633
Change from Baseline: Day 80.12 ± 0.766-0.02 ± 0.887-0.05 ± 0.779
Change from Baseline: Day 15 (Pre-CAE)0.00 ± 0.869-0.24 ± 0.831-0.09 ± 0.780
Change from Baseline: Day 15 (Post-CAE)-0.52 ± 0.749-0.58 ± 0.732-0.42 ± 0.724
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.52 ± 0.963-0.34 ± 0.923-0.33 ± 0.956
Change from Baseline: Day 29 (Pre-CAE)0.01 ± 0.906-0.21 ± 0.771-0.07 ± 0.776
Change from Baseline: Day 29 (Post-CAE)-0.50 ± 0.612-0.54 ± 0.528-0.16 ± 0.653
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.69 ± 0.870-0.54 ± 0.948-0.20 ± 0.916
Change from Baseline: Day 57 (Pre-CAE)0.00 ± 0.837-0.10 ± 0.832-0.20 ± 0.802
Change from Baseline: Day 57 (Post-CAE)-0.36 ± 0.765-0.35 ± 0.856-0.30 ± 0.847
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.36 ± 1.089-0.23 ± 1.043-0.13 ± 0.846
SecondaryMean Change From Baseline in Fluorescein Staining (Temporal Region)

It is evaluated for the temporal region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Fluorescein Staining (Temporal Region)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE2.14 ± 0.4522.12 ± 0.5212.02 ± 0.622
Day 1 Post-CAE2.60 ± 0.6062.42 ± 0.5382.47 ± 0.519
Day 1 (Change from Pre-CAE to Post-CAE)0.46 ± 0.5230.30 ± 0.6470.45 ± 0.625
Change from Baseline: Day 8-0.01 ± 0.520-0.09 ± 0.598-0.13 ± 0.755
Change from Baseline: Day 15 (Pre-CAE)-0.34 ± 0.601-0.31 ± 0.741-0.14 ± 0.736
Change from Baseline: Day 15 (Post-CAE)-0.49 ± 0.739-0.54 ± 0.683-0.54 ± 0.552
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.15 ± 0.835-0.23 ± 0.765-0.40 ± 0.857
Change from Baseline: Day 29 (Pre-CAE)-0.19 ± 0.706-0.18 ± 0.828-0.10 ± 0.714
Change from Baseline: Day 29 (Post-CAE)-0.34 ± 0.569-0.38 ± 0.653-0.20 ± 0.478
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.26 ± 0.872-0.33 ± 0.894-0.20 ± 0.737
Change from Baseline: Day 57 (Pre-CAE)-0.07 ± 0.5540.06 ± 0.749-0.09 ± 0.754
Change from Baseline: Day 57 (Post-CAE)-0.30 ± 0.679-0.24 ± 0.767-0.33 ± 0.696
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.24 ± 0.842-0.28 ± 0.902-0.26 ± 0.824
SecondaryMean Change From Baseline in Fluorescein Staining (Nasal Region)

It is evaluated for the nasal region on the Ora Calibra® Corneal and Conjunctival staining scale. The score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Fluorescein Staining (Nasal Region)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE2.27 ± 0.5072.26 ± 0.5272.14 ± 0.544
Day 1 Post-CAE2.74 ± 0.6492.67 ± 0.5772.68 ± 0.587
Day 1 (Change from Pre-CAE to Post-CAE)0.47 ± 0.5570.41 ± 0.5410.54 ± 0.638
Change from Baseline: Day 8-0.06 ± 0.501-0.05 ± 0.518-0.05 ± 0.702
Change from Baseline: Day 15 (Pre-CAE)-0.28 ± 0.743-0.29 ± 0.600-0.06 ± 0.620
Change from Baseline: Day 15 (Post-CAE)-0.44 ± 0.697-0.52 ± 0.785-0.51 ± 0.773
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.16 ± 0.830-0.23 ± 0.772-0.45 ± 0.859
Change from Baseline: Day 29 (Pre-CAE)-0.20 ± 0.735-0.18 ± 0.688-0.04 ± 0.783
Change from Baseline: Day 29 (Post-CAE)-0.17 ± 0.658-0.19 ± 0.694-0.20 ± 0.643
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.03 ± 0.755-0.06 ± 0.589-0.17 ± 0.877
Change from Baseline: Day 57 (Pre-CAE)-0.01 ± 0.7710.01 ± 0.678-0.24 ± 0.600
Change from Baseline: Day 57 (Post-CAE)-0.29 ± 0.671-0.26 ± 0.960-0.38 ± 0.718
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.28 ± 0.696-0.27 ± 0.928-0.15 ± 0.805
SecondaryMean Change From Baseline in Fluorescein Staining (Corneal Sum)

Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Corneal sum score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Fluorescein Staining (Corneal Sum)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE5.44 ± 1.2325.61 ± 1.2305.47 ± 1.154
Day 1 Post-CAE8.23 ± 1.3187.90 ± 1.2417.69 ± 1.340
Day 1 (Change from Pre-CAE to Post-CAE)2.79 ± 1.2582.29 ± 1.2462.22 ± 1.135
Change from Baseline: Day 80.22 ± 1.559-0.30 ± 1.584-0.10 ± 1.544
Change from Baseline: Day 15 (Pre-CAE)-0.34 ± 1.939-0.89 ± 1.562-0.48 ± 1.474
Change from Baseline: Day 15 (Post-CAE)-1.80 ± 2.058-2.16 ± 1.695-1.45 ± 1.526
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-1.46 ± 1.935-1.27 ± 1.516-0.97 ± 1.739
Change from Baseline: Day 29 (Pre-CAE)-0.22 ± 1.995-0.42 ± 1.404-0.17 ± 1.704
Change from Baseline: Day 29 (Post-CAE)-1.41 ± 1.389-2.02 ± 1.360-0.71 ± 1.205
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-1.76 ± 1.850-2.08 ± 1.659-0.93 ± 1.438
Change from Baseline: Day 57 (Pre-CAE)0.03 ± 1.470-0.14 ± 1.579-0.41 ± 1.634
Change from Baseline: Day 57 (Post-CAE)-1.28 ± 1.618-1.56 ± 1.780-1.16 ± 1.748
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-1.32 ± 2.034-1.36 ± 1.881-0.84 ± 1.801
SecondaryMean Change From Baseline in Fluorescein Staining (Conjunctival Sum)

Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Conjunctival sum score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Fluorescein Staining (Conjunctival Sum)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE4.41 ± 0.8794.38 ± 0.9234.16 ± 1.052
Day 1 Post-CAE5.34 ± 1.1185.09 ± 0.9415.15 ± 0.981
Day 1 (Change from Pre-CAE to Post-CAE)0.93 ± 0.8270.71 ± 0.9640.99 ± 1.095
Change from Baseline: Day 8-0.07 ± 0.845-0.15 ± 0.875-0.18 ± 1.349
Change from Baseline: Day 15 (Pre-CAE)-0.62 ± 1.167-0.60 ± 1.158-0.20 ± 1.143
Change from Baseline: Day 15 (Post-CAE)-0.93 ± 1.212-1.06 ± 1.295-1.05 ± 1.135
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.31 ± 1.269-0.46 ± 1.258-0.85 ± 1.440
Change from Baseline: Day 29 (Pre-CAE)-0.39 ± 1.263-0.35 ± 1.360-0.14 ± 1.327
Change from Baseline: Day 29 (Post-CAE)-0.52 ± 0.986-0.58 ± 1.206-0.39 ± 0.927
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.29 ± 1.379-0.38 ± 1.219-0.37 ± 1.377
Change from Baseline: Day 57 (Pre-CAE)-0.08 ± 1.1780.07 ± 1.269-0.33 ± 1.223
Change from Baseline: Day 57 (Post-CAE)-0.60 ± 1.177-0.50 ± 1.528-0.70 ± 1.194
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.52 ± 1.273-0.55 ± 1.573-0.41 ± 1.306
SecondaryMean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)

Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the Ora Calibra® Corneal and Conjunctival staining scale. Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Fluorescein Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE9.85 ± 1.8529.99 ± 1.7779.63 ± 1.982
Day 1 Post-CAE13.57 ± 2.14312.99 ± 1.82812.84 ± 1.872
Day 1 (Change from Pre-CAE to Post-CAE)3.72 ± 1.6143.00 ± 1.6843.21 ± 1.890
Change from Baseline: Day 80.15 ± 2.139-0.45 ± 2.009-0.29 ± 2.667
Change from Baseline: Day 15 (Pre-CAE)-0.96 ± 2.866-1.49 ± 2.312-0.68 ± 2.338
Change from Baseline: Day 15 (Post-CAE)-2.73 ± 2.875-3.22 ± 2.664-2.50 ± 2.150
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-1.77 ± 2.686-1.73 ± 2.245-1.82 ± 2.676
Change from Baseline: Day 29 (Pre-CAE)-0.61 ± 2.933-0.77 ± 2.214-0.30 ± 2.710
Change from Baseline: Day 29 (Post-CAE)-1.93 ± 1.831-2.60 ± 2.168-1.11 ± 1.739
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-2.05 ± 2.530-2.46 ± 2.054-1.30 ± 2.403
Change from Baseline: Day 57 (Pre-CAE)-0.04 ± 2.250-0.07 ± 2.403-0.74 ± 2.560
Change from Baseline: Day 57 (Post-CAE)-1.88 ± 2.400-2.06 ± 2.990-1.87 ± 2.559
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-1.84 ± 2.763-1.91 ± 2.922-1.24 ± 2.387
SecondaryMean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)

It is evaluated for the inferior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Lissamine Green Staining Total Score (Inferior Region)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE1.42 ± 0.6421.46 ± 0.6051.50 ± 0.580
Day 1 Post-CAE2.00 ± 0.9202.12 ± 0.8951.87 ± 0.826
Day 1 (Change from Pre-CAE to Post-CAE)0.58 ± 0.7520.66 ± 0.9340.37 ± 0.850
Change from Baseline: Day 80.04 ± 0.699-0.30 ± 0.642-0.08 ± 0.702
Change from Baseline: Day 15 (Pre-CAE)-0.34 ± 0.805-0.43 ± 0.644-0.48 ± 0.707
Change from Baseline: Day 15 (Post-CAE)-0.46 ± 1.228-0.76 ± 0.984-0.34 ± 1.104
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.12 ± 0.982-0.33 ± 0.9190.14 ± 1.170
Change from Baseline: Day 29 (Pre-CAE)-0.14 ± 0.815-0.24 ± 0.715-0.28 ± 0.607
Change from Baseline: Day 29 (Post-CAE)-0.10 ± 1.191-0.69 ± 0.895-0.20 ± 1.074
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.10 ± 1.064-0.60 ± 0.9490.16 ± 1.147
Change from Baseline: Day 57 (Pre-CAE)-0.21 ± 0.637-0.17 ± 0.869-0.34 ± 0.688
Change from Baseline: Day 57 (Post-CAE)-0.16 ± 0.943-0.60 ± 0.877-0.22 ± 0.764
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)0.04 ± 0.881-0.38 ± 1.1790.07 ± 0.866
SecondaryMean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)

It is evaluated for the superior region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Lissamine Green Staining Total Score (Superior Region)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE1.22 ± 0.5071.32 ± 0.5601.27 ± 0.546
Day 1 Post-CAE1.48 ± 0.5801.51 ± 0.7031.44 ± 0.697
Day 1 (Change from Pre-CAE to Post-CAE)0.26 ± 0.5270.19 ± 0.6690.17 ± 0.760
Change from Baseline: Day 8-0.14 ± 0.525-0.31 ± 0.624-0.18 ± 0.537
Change from Baseline: Day 15 (Pre-CAE)-0.37 ± 0.838-0.57 ± 0.772-0.38 ± 0.907
Change from Baseline: Day 15 (Post-CAE)-0.48 ± 0.931-0.66 ± 0.870-0.34 ± 0.866
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.11 ± 0.841-0.08 ± 0.8080.04 ± 0.936
Change from Baseline: Day 29 (Pre-CAE)-0.29 ± 0.729-0.33 ± 0.604-0.44 ± 0.712
Change from Baseline: Day 29 (Post-CAE)-0.19 ± 0.806-0.31 ± 0.8490.02 ± 0.713
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.14 ± 0.789-0.04 ± 0.9160.30 ± 0.896
Change from Baseline: Day 57 (Pre-CAE)-0.32 ± 0.541-0.36 ± 0.694-0.40 ± 0.769
Change from Baseline: Day 57 (Post-CAE)-0.37 ± 0.679-0.44 ± 0.717-0.28 ± 0.736
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.05 ± 0.797-0.05 ± 0.7620.08 ± 0.915
SecondaryMean Change From Baseline in Lissamine Green Staining Total Score (Central Region)

It is evaluated for the central region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Lissamine Green Staining Total Score (Central Region)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE0.48 ± 0.7350.57 ± 0.7420.54 ± 0.734
Day 1 Post-CAE0.59 ± 0.7800.60 ± 0.7350.66 ± 0.823
Day 1 (Change from Pre-CAE to Post-CAE)0.11 ± 0.5470.03 ± 0.5190.12 ± 0.799
Change from Baseline: Day 8-0.13 ± 0.676-0.29 ± 0.582-0.24 ± 0.723
Change from Baseline: Day 15 (Pre-CAE)-0.13 ± 0.720-0.26 ± 0.636-0.24 ± 0.744
Change from Baseline: Day 15 (Post-CAE)-0.33 ± 0.636-0.29 ± 0.706-0.30 ± 0.647
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.20 ± 0.776-0.03 ± 0.815-0.06 ± 0.935
Change from Baseline: Day 29 (Pre-CAE)-0.31 ± 0.630-0.22 ± 0.837-0.28 ± 0.730
Change from Baseline: Day 29 (Post-CAE)-0.07 ± 0.258-0.15 ± 0.660-0.07 ± 0.466
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)0.03 ± 0.680-0.17 ± 0.6770.11 ± 0.956
Change from Baseline: Day 57 (Pre-CAE)-0.23 ± 0.555-0.31 ± 0.667-0.16 ± 0.681
Change from Baseline: Day 57 (Post-CAE)-0.14 ± 0.602-0.34 ± 0.898-0.31 ± 0.619
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)0.09 ± 0.652-0.02 ± 0.879-0.18 ± 0.782
SecondaryMean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)

It is evaluated for the temporal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Lissamine Green Staining Total Score (Temporal Region)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE1.63 ± 0.7061.63 ± 0.6691.61 ± 0.751
Day 1 Post-CAE1.87 ± 0.6911.71 ± 0.6711.87 ± 0.734
Day 1 (Change from Pre-CAE to Post-CAE)0.24 ± 0.6490.08 ± 0.6950.26 ± 0.834
Change from Baseline: Day 8-0.09 ± 0.733-0.11 ± 0.864-0.15 ± 0.686
Change from Baseline: Day 15 (Pre-CAE)-0.32 ± 0.885-0.48 ± 0.707-0.46 ± 0.885
Change from Baseline: Day 15 (Post-CAE)-0.37 ± 0.669-0.50 ± 0.772-0.50 ± 0.606
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.05 ± 0.876-0.02 ± 0.928-0.04 ± 0.919
Change from Baseline: Day 29 (Pre-CAE)-0.29 ± 0.915-0.21 ± 0.683-0.19 ± 0.630
Change from Baseline: Day 29 (Post-CAE)-0.28 ± 0.663-0.06 ± 0.668-0.25 ± 0.569
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.09 ± 1.1420.08 ± 0.688-0.05 ± 0.916
Change from Baseline: Day 57 (Pre-CAE)-0.26 ± 0.721-0.20 ± 0.816-0.16 ± 0.710
Change from Baseline: Day 57 (Post-CAE)-0.21 ± 0.750-0.22 ± 0.934-0.22 ± 0.715
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)0.05 ± 1.0290.03 ± 0.947-0.07 ± 1.066
SecondaryMean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)

It is evaluated for the nasal region on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Lissamine Green Staining Total Score (Nasal Region)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE1.90 ± 0.7071.96 ± 0.5611.69 ± 0.638
Day 1 Post-CAE2.18 ± 0.7742.05 ± 0.8281.93 ± 0.693
Day 1 (Change from Pre-CAE to Post-CAE)0.28 ± 0.6400.09 ± 0.7400.24 ± 0.816
Change from Baseline: Day 8-0.04 ± 0.748-0.25 ± 0.6680.00 ± 0.677
Change from Baseline: Day 15 (Pre-CAE)-0.22 ± 0.723-0.48 ± 0.660-0.23 ± 0.822
Change from Baseline: Day 15 (Post-CAE)-0.23 ± 0.858-0.29 ± 0.904-0.24 ± 0.672
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.01 ± 0.9010.19 ± 1.070-0.01 ± 1.013
Change from Baseline: Day 29 (Pre-CAE)-0.28 ± 0.679-0.39 ± 0.638-0.03 ± 0.785
Change from Baseline: Day 29 (Post-CAE)-0.19 ± 0.7370.10 ± 0.749-0.11 ± 0.854
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)0.09 ± 0.7800.52 ± 0.781-0.02 ± 1.004
Change from Baseline: Day 57 (Pre-CAE)-0.12 ± 0.709-0.31 ± 0.692-0.10 ± 0.721
Change from Baseline: Day 57 (Post-CAE)-0.26 ± 0.815-0.16 ± 0.843-0.02 ± 0.841
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.14 ± 0.8210.17 ± 0.8720.05 ± 0.959
SecondaryMean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)

Corneal sum score is the sum of all regions of the cornea (inferior, superior and central regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 12. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Lissamine Green Staining Total Score (Corneal Sum)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE3.12 ± 1.2723.35 ± 1.3603.31 ± 1.344
Day 1 Post-CAE4.07 ± 1.7054.23 ± 1.7853.97 ± 1.828
Day 1 (Change from Pre-CAE to Post-CAE)0.95 ± 1.3140.88 ± 1.6830.66 ± 1.701
Change from Baseline: Day 8-0.23 ± 1.258-0.91 ± 1.382-0.51 ± 1.375
Change from Baseline: Day 15 (Pre-CAE)-0.84 ± 1.633-1.26 ± 1.568-1.10 ± 1.909
Change from Baseline: Day 15 (Post-CAE)-1.27 ± 2.264-1.71 ± 2.118-0.98 ± 1.924
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.43 ± 1.648-0.45 ± 1.9520.12 ± 1.965
Change from Baseline: Day 29 (Pre-CAE)-0.74 ± 1.516-0.79 ± 1.487-1.00 ± 1.488
Change from Baseline: Day 29 (Post-CAE)-0.36 ± 1.782-1.15 ± 1.754-0.25 ± 1.430
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.21 ± 1.578-0.81 ± 1.5880.57 ± 1.783
Change from Baseline: Day 57 (Pre-CAE)-0.75 ± 1.228-0.84 ± 1.751-0.90 ± 1.793
Change from Baseline: Day 57 (Post-CAE)-0.67 ± 1.674-1.38 ± 1.936-0.81 ± 1.439
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)0.08 ± 1.494-0.45 ± 2.154-0.03 ± 1.586
SecondaryMean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)

Conjunctival sum score is the sum of all regions of the conjunctiva (temporal and nasal regions). Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 8. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Lissamine Green Staining Total Score (Conjunctival Sum)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE3.53 ± 1.2313.59 ± 1.0583.30 ± 1.237
Day 1 Post-CAE4.05 ± 1.3143.76 ± 1.3223.80 ± 1.262
Day 1 (Change from Pre-CAE to Post-CAE)0.52 ± 1.0920.17 ± 1.2230.50 ± 1.403
Change from Baseline: Day 8-0.13 ± 1.249-0.36 ± 1.197-0.15 ± 1.133
Change from Baseline: Day 15 (Pre-CAE)-0.54 ± 1.417-0.96 ± 1.056-0.69 ± 1.548
Change from Baseline: Day 15 (Post-CAE)-0.60 ± 1.245-0.79 ± 1.228-0.74 ± 1.084
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.06 ± 1.4270.17 ± 1.524-0.05 ± 1.724
Change from Baseline: Day 29 (Pre-CAE)-0.57 ± 1.336-0.59 ± 1.090-0.22 ± 1.112
Change from Baseline: Day 29 (Post-CAE)-0.47 ± 1.1950.04 ± 1.264-0.36 ± 1.154
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)0.00 ± 1.5530.60 ± 1.200-0.07 ± 1.412
Change from Baseline: Day 57 (Pre-CAE)-0.38 ± 1.175-0.51 ± 1.349-0.26 ± 1.222
Change from Baseline: Day 57 (Post-CAE)-0.47 ± 1.356-0.38 ± 1.577-0.24 ± 1.377
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.09 ± 1.6680.21 ± 1.461-0.02 ± 1.723
SecondaryMean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)

Total score was sum of all 5 regions: central, superior, inferior, temporal, and nasal. Individual region score was evaluated on the lissamine green corneal and conjunctival staining scale (Ora Calibra® scale). Individual region score ranges from 0 to 4 (0=none and 4=severe), and lower score indicates improvement. Total score ranges from 0 to 20. Change score from pre- to post-CAE® was calculated as post-CAE® score - pre-CAE® score.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Mean Change From Baseline in Lissamine Green Staining Total Score (All Five Regions: Central, Superior, Inferior, Temporal, Nasal)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE6.65 ± 2.2776.94 ± 2.0916.61 ± 2.223
Day 1 Post-CAE8.12 ± 2.6537.99 ± 2.7537.77 ± 2.741
Day 1 (Change from Pre-CAE to Post-CAE)1.47 ± 1.9231.05 ± 2.4931.16 ± 2.708
Change from Baseline: Day 8-0.36 ± 2.124-1.27 ± 2.065-0.66 ± 2.090
Change from Baseline: Day 15 (Pre-CAE)-1.38 ± 2.767-2.22 ± 2.193-1.79 ± 3.059
Change from Baseline: Day 15 (Post-CAE)-1.87 ± 3.156-2.50 ± 2.836-1.72 ± 2.607
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.49 ± 2.409-0.28 ± 2.6330.07 ± 3.161
Change from Baseline: Day 29 (Pre-CAE)-1.31 ± 2.435-1.39 ± 2.038-1.22 ± 2.150
Change from Baseline: Day 29 (Post-CAE)-0.83 ± 2.369-1.12 ± 2.455-0.61 ± 2.025
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.21 ± 2.551-0.21 ± 2.0160.50 ± 2.553
Change from Baseline: Day 57 (Pre-CAE)-1.13 ± 1.815-1.35 ± 2.684-1.16 ± 2.616
Change from Baseline: Day 57 (Post-CAE)-1.14 ± 2.635-1.77 ± 3.087-1.05 ± 2.424
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.01 ± 2.568-0.24 ± 3.138-0.05 ± 2.716
SecondaryChange From Baseline in Tear Film Break-Up Time

Sodium fluorescein solution was instilled into each eye and participants were instructed to blinked several times. The time it takes to form micelles from the time that the eye is opened was noted.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · seconds
Change From Baseline in Tear Film Break-Up Time
seconds0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE1.559 ± 0.50311.709 ± 0.70831.574 ± 0.5394
Day 1 Post-CAE1.533 ± 0.52171.555 ± 0.54411.574 ± 0.5322
Day 1 (Change from Pre-CAE to Post-CAE)-0.027 ± 0.4552-0.154 ± 0.5516-0.001 ± 0.3670
Change from Baseline: Day 80.024 ± 0.4943-0.037 ± 0.7421-0.036 ± 0.4948
Change from Baseline: Day 15 (Pre-CAE)0.386 ± 0.80080.127 ± 0.79450.276 ± 0.7857
Change from Baseline: Day 15 (Post-CAE)0.312 ± 0.94700.195 ± 0.68350.222 ± 0.7884
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.075 ± 0.73550.068 ± 0.6543-0.054 ± 0.6252
Change from Baseline: Day 29 (Pre-CAE)0.218 ± 0.7586-0.191 ± 0.5936-0.077 ± 0.5228
Change from Baseline: Day 29 (Post-CAE)0.123 ± 0.71160.086 ± 0.6752-0.188 ± 0.3884
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.054 ± 0.50130.129 ± 0.4258-0.119 ± 0.5623
Change from Baseline: Day 57 (Pre-CAE)0.139 ± 0.5727-0.036 ± 0.88800.186 ± 0.6696
Change from Baseline: Day 57 (Post-CAE)0.118 ± 0.70720.039 ± 0.60570.160 ± 0.7206
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.021 ± 0.61130.063 ± 0.8557-0.003 ± 0.6473
SecondaryChange From Baseline in the Ora Calibra® Conjunctival Redness Scale

It is evaluated by the Ora Calibra® conjunctival redness scale for dry eye. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Change From Baseline in the Ora Calibra® Conjunctival Redness Scale
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE1.70 ± 0.6391.66 ± 0.5661.72 ± 0.536
Day 1 Post-CAE2.03 ± 0.6262.02 ± 0.5712.04 ± 0.523
Day 1 (Change from Pre-CAE to Post-CAE)0.33 ± 0.6030.36 ± 0.6550.32 ± 0.569
Change from Baseline: Day 80.04 ± 0.588-0.07 ± 0.4730.00 ± 0.669
Change from Baseline: Day 15 (Pre-CAE)-0.20 ± 0.606-0.17 ± 0.559-0.17 ± 0.568
Change from Baseline: Day 15 (Post-CAE)-0.14 ± 0.663-0.35 ± 0.515-0.20 ± 0.606
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)0.06 ± 0.983-0.19 ± 0.836-0.03 ± 0.785
Change from Baseline: Day 29 (Pre-CAE)-0.06 ± 0.740-0.03 ± 0.614-0.10 ± 0.685
Change from Baseline: Day 29 (Post-CAE)-0.22 ± 0.635-0.31 ± 0.601-0.21 ± 0.568
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.05 ± 0.967-0.21 ± 0.907-0.11 ± 1.012
Change from Baseline: Day 57 (Pre-CAE)0.01 ± 0.5630.23 ± 0.6600.11 ± 0.565
Change from Baseline: Day 57 (Post-CAE)-0.03 ± 0.591-0.01 ± 0.728-0.14 ± 0.586
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.04 ± 0.788-0.22 ± 0.941-0.28 ± 0.708
SecondaryChange From Baseline in Schirmer's Test

The Schirmer test strip will be placed in the lower temporal lid margin of each eye. Subjects will be instructed to close their eyes and After 5 minutes have elapsed, The length of moistened area of schirmer strip will be recorded (mm) for each eye.

Time frame:
Baseline (Day 1); Days 15, 29, and 57
Reported as:
Mean · mm
Change From Baseline in Schirmer's Test
mm0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 15.0 ± 2.605.2 ± 3.035.5 ± 3.02
Change From Baseline: Day 151.7 ± 5.214.0 ± 7.363.4 ± 6.50
Change From Baseline: Day 290.8 ± 5.010.9 ± 4.231.8 ± 4.35
Change From Baseline: Day 573.5 ± 6.702.9 ± 4.743.3 ± 6.84
SecondaryChange From Baseline in Ora Calibra® Ocular Discomfort Scale

It was assessed by the Ora Calibra® ocular discomfort scale. The score ranges from 0 to 4 (0=none and 4=severe), where lower score indicates improvement.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Change From Baseline in Ora Calibra® Ocular Discomfort Scale
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE2.6 ± 0.862.5 ± 0.952.4 ± 0.75
Day 1 Post-CAE3.8 ± 0.523.7 ± 0.473.8 ± 0.52
Day 1 (Change from Pre-CAE to Post-CAE)1.2 ± 0.981.2 ± 1.011.4 ± 0.81
Change from Baseline: Day 8-0.5 ± 0.890.1 ± 0.81-0.1 ± 1.01
Change from Baseline: Day 15 (Pre-CAE)-0.5 ± 0.71-0.1 ± 0.96-0.1 ± 0.87
Change from Baseline: Day 15 (Post-CAE)0.0 ± 0.620.0 ± 0.580.0 ± 0.55
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)0.5 ± 0.910.1 ± 1.130.1 ± 1.05
Change from Baseline: Day 29 (Pre-CAE)-0.4 ± 1.03-0.3 ± 0.92-0.2 ± 1.05
Change from Baseline: Day 29 (Post-CAE)0.0 ± 0.63-0.2 ± 0.630.0 ± 0.88
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)0.5 ± 1.180.0 ± 1.110.1 ± 1.36
Change from Baseline: Day 57 (Pre-CAE)-0.5 ± 1.17-0.4 ± 1.39-0.1 ± 0.88
Change from Baseline: Day 57 (Post-CAE)-0.2 ± 0.77-0.1 ± 0.65-0.2 ± 0.76
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)0.3 ± 1.300.4 ± 1.43-0.1 ± 1.17
SecondaryChange From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of overall ocular discomfort at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE2.9 ± 0.882.7 ± 1.092.8 ± 0.78
Day 1 Post-CAE3.8 ± 0.573.7 ± 0.814.0 ± 0.74
Day 1 (Change from Pre-CAE to Post-CAE)0.9 ± 0.821.0 ± 1.111.2 ± 0.92
Change from Baseline: Day 8-0.3 ± 0.970.0 ± 0.98-0.2 ± 0.90
Change from Baseline: Day 15 (Pre-CAE)-0.4 ± 0.930.0 ± 1.00-0.1 ± 0.97
Change from Baseline: Day 15 (Post-CAE)-0.2 ± 0.780.0 ± 0.66-0.2 ± 0.95
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)0.2 ± 1.130.0 ± 1.070.0 ± 1.40
Change from Baseline: Day 29 (Pre-CAE)-0.3 ± 1.05-0.3 ± 1.19-0.3 ± 1.17
Change from Baseline: Day 29 (Post-CAE)-0.1 ± 0.900.0 ± 0.89-0.1 ± 0.72
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)0.3 ± 1.030.3 ± 1.230.2 ± 1.49
Change from Baseline: Day 57 (Pre-CAE)-0.5 ± 1.35-0.4 ± 1.35-0.2 ± 1.06
Change from Baseline: Day 57 (Post-CAE)-0.2 ± 0.860.0 ± 0.64-0.4 ± 0.98
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)0.3 ± 1.470.5 ± 1.32-0.1 ± 1.33
SecondaryChange From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of burning at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE1.6 ± 1.311.4 ± 1.351.2 ± 1.28
Day 1 Post-CAE2.5 ± 1.492.3 ± 1.552.4 ± 1.66
Day 1 (Change from Pre-CAE to Post-CAE)1.0 ± 1.260.9 ± 1.121.2 ± 1.29
Change from Baseline: Day 8-0.1 ± 0.810.0 ± 0.920.0 ± 0.85
Change from Baseline: Day 15 (Pre-CAE)-0.1 ± 1.04-0.2 ± 1.140.0 ± 0.74
Change from Baseline: Day 15 (Post-CAE)-0.1 ± 1.160.0 ± 1.17-0.1 ± 1.05
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)0.0 ± 1.620.2 ± 1.40-0.1 ± 1.40
Change from Baseline: Day 29 (Pre-CAE)-0.1 ± 1.14-0.2 ± 1.180.0 ± 0.84
Change from Baseline: Day 29 (Post-CAE)-0.1 ± 1.35-0.2 ± 0.97-0.1 ± 0.85
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)0.1 ± 1.250.4 ± 1.24-0.3 ± 1.21
Change from Baseline: Day 57 (Pre-CAE)-0.1 ± 1.22-0.5 ± 1.50-0.1 ± 0.93
Change from Baseline: Day 57 (Post-CAE)-0.2 ± 1.09-0.1 ± 1.28-0.3 ± 1.01
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.1 ± 1.480.5 ± 1.26-0.2 ± 1.30
SecondaryChange From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of dryness at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE3.1 ± 0.873.1 ± 1.033.0 ± 0.84
Day 1 Post-CAE4.0 ± 0.713.9 ± 0.804.1 ± 0.63
Day 1 (Change from Pre-CAE to Post-CAE)1.0 ± 0.860.9 ± 0.761.1 ± 0.99
Change from Baseline: Day 8-0.4 ± 0.90-0.1 ± 0.70-0.2 ± 0.77
Change from Baseline: Day 15 (Pre-CAE)-0.3 ± 0.80-0.2 ± 0.90-0.1 ± 0.76
Change from Baseline: Day 15 (Post-CAE)-0.2 ± 0.71-0.2 ± 0.80-0.1 ± 0.95
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)0.1 ± 1.080.0 ± 0.980.0 ± 1.29
Change from Baseline: Day 29 (Pre-CAE)-0.2 ± 1.03-0.4 ± 1.01-0.3 ± 0.94
Change from Baseline: Day 29 (Post-CAE)-0.3 ± 1.04-0.2 ± 0.67-0.2 ± 0.79
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)0.0 ± 0.980.5 ± 1.170.1 ± 1.33
Change from Baseline: Day 57 (Pre-CAE)-0.4 ± 1.25-0.3 ± 1.20-0.2 ± 1.08
Change from Baseline: Day 57 (Post-CAE)-0.2 ± 0.85-0.1 ± 0.82-0.3 ± 1.09
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)0.1 ± 1.310.3 ± 1.04-0.1 ± 1.36
SecondaryChange From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of grittiness at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE2.1 ± 1.271.8 ± 1.472.0 ± 1.35
Day 1 Post-CAE2.7 ± 1.402.3 ± 1.633.0 ± 1.28
Day 1 (Change from Pre-CAE to Post-CAE)0.7 ± 1.100.5 ± 0.961.1 ± 1.10
Change from Baseline: Day 8-0.2 ± 1.06-0.1 ± 0.670.1 ± 0.95
Change from Baseline: Day 15 (Pre-CAE)-0.1 ± 1.050.2 ± 1.060.0 ± 0.68
Change from Baseline: Day 15 (Post-CAE)-0.1 ± 1.000.2 ± 1.24-0.3 ± 1.07
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)0.0 ± 1.290.0 ± 1.03-0.3 ± 1.33
Change from Baseline: Day 29 (Pre-CAE)-0.2 ± 1.25-0.1 ± 1.18-0.2 ± 1.04
Change from Baseline: Day 29 (Post-CAE)-0.2 ± 0.990.1 ± 1.03-0.1 ± 0.74
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)0.1 ± 1.180.3 ± 1.010.0 ± 1.22
Change from Baseline: Day 57 (Pre-CAE)-0.4 ± 1.20-0.1 ± 1.29-0.1 ± 0.94
Change from Baseline: Day 57 (Post-CAE)-0.3 ± 1.060.2 ± 1.13-0.6 ± 1.08
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)0.0 ± 1.440.3 ± 1.09-0.4 ± 1.14
SecondaryChange From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of stinging at all scheduled visits on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity.

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · score on a scale
Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE1.5 ± 1.331.2 ± 1.351.0 ± 1.08
Day 1 Post-CAE2.3 ± 1.421.9 ± 1.552.0 ± 1.67
Day 1 (Change from Pre-CAE to Post-CAE)0.8 ± 1.180.7 ± 1.051.0 ± 1.26
Change from Baseline: Day 8-0.3 ± 0.92-0.2 ± 0.86-0.1 ± 0.69
Change from Baseline: Day 15 (Pre-CAE)-0.2 ± 1.04-0.2 ± 1.080.0 ± 0.76
Change from Baseline: Day 15 (Post-CAE)-0.3 ± 1.120.0 ± 1.00-0.1 ± 1.19
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)0.0 ± 1.340.2 ± 1.24-0.1 ± 1.41
Change from Baseline: Day 29 (Pre-CAE)-0.2 ± 1.12-0.3 ± 1.03-0.1 ± 0.90
Change from Baseline: Day 29 (Post-CAE)-0.3 ± 1.23-0.4 ± 1.06-0.2 ± 1.28
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)0.0 ± 1.160.1 ± 1.06-0.2 ± 1.47
Change from Baseline: Day 57 (Pre-CAE)-0.2 ± 1.35-0.3 ± 1.40-0.1 ± 1.01
Change from Baseline: Day 57 (Post-CAE)-0.3 ± 1.12-0.1 ± 1.28-0.4 ± 1.30
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)0.0 ± 1.830.3 ± 1.41-0.3 ± 1.51
SecondaryChange From Baseline in Visual Analog Scale (Burning)

Participants rated ocular symptom of burning by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · mm
Change From Baseline in Visual Analog Scale (Burning)
mm0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE30.4 ± 28.5329.3 ± 26.7422.4 ± 24.60
Day 1 Post-CAE44.6 ± 29.9944.1 ± 33.9140.1 ± 32.15
Day 1 (Change from Pre-CAE to Post-CAE)14.2 ± 23.5714.5 ± 22.2717.7 ± 22.75
Change from Baseline: Day 8-1.9 ± 19.34-4.5 ± 25.730.5 ± 16.66
Change from Baseline: Day 15 (Pre-CAE)-3.0 ± 19.75-6.7 ± 24.080.3 ± 11.84
Change from Baseline: Day 15 (Post-CAE)-1.6 ± 23.56-10.8 ± 24.27-2.2 ± 16.90
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)1.4 ± 26.91-3.5 ± 21.46-2.6 ± 17.42
Change from Baseline: Day 29 (Pre-CAE)-3.0 ± 26.13-6.6 ± 26.82-0.4 ± 15.67
Change from Baseline: Day 29 (Post-CAE)-7.3 ± 21.43-8.8 ± 26.93-3.2 ± 16.00
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-0.2 ± 23.762.4 ± 25.72-4.0 ± 24.77
Change from Baseline: Day 57 (Pre-CAE)-3.5 ± 27.19-10.0 ± 31.76-1.5 ± 16.19
Change from Baseline: Day 57 (Post-CAE)-1.3 ± 20.26-10.3 ± 26.98-4.6 ± 21.47
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)2.2 ± 33.082.2 ± 30.19-3.0 ± 23.35
SecondaryChange From Baseline in Visual Analog Scale (Itching)

Participants rated ocular symptom of itching by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · mm
Change From Baseline in Visual Analog Scale (Itching)
mm0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE28.6 ± 27.0926.2 ± 29.2626.8 ± 23.70
Day 1 Post-CAE37.0 ± 30.4531.9 ± 33.2635.0 ± 28.92
Day 1 (Change from Pre-CAE to Post-CAE)8.4 ± 21.675.2 ± 18.008.2 ± 22.76
Change from Baseline: Day 8-6.0 ± 19.05-2.8 ± 22.230.5 ± 19.54
Change from Baseline: Day 15 (Pre-CAE)-3.1 ± 19.18-4.5 ± 18.281.6 ± 20.27
Change from Baseline: Day 15 (Post-CAE)-8.0 ± 22.37-2.4 ± 19.211.9 ± 16.56
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-4.9 ± 27.232.2 ± 21.180.3 ± 19.52
Change from Baseline: Day 29 (Pre-CAE)-2.7 ± 24.78-9.5 ± 20.74-1.7 ± 20.97
Change from Baseline: Day 29 (Post-CAE)-9.3 ± 19.47-6.2 ± 23.642.2 ± 23.30
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-3.6 ± 15.785.2 ± 26.673.6 ± 25.99
Change from Baseline: Day 57 (Pre-CAE)-6.8 ± 22.73-8.1 ± 27.02-1.2 ± 23.65
Change from Baseline: Day 57 (Post-CAE)-7.0 ± 27.35-5.7 ± 23.95-2.1 ± 19.13
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-0.2 ± 25.654.7 ± 22.750.2 ± 26.94
SecondaryChange From Baseline in Visual Analog Scale (Foreign Body)

Participants rated ocular symptom of foreign body by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · mm
Change From Baseline in Visual Analog Scale (Foreign Body)
mm0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE35.3 ± 25.9535.1 ± 29.1934.1 ± 25.87
Day 1 Post-CAE45.1 ± 29.5443.1 ± 31.0349.9 ± 27.82
Day 1 (Change from Pre-CAE to Post-CAE)9.8 ± 24.258.1 ± 22.3015.8 ± 21.57
Change from Baseline: Day 8-6.2 ± 23.33-3.4 ± 16.32-0.4 ± 19.69
Change from Baseline: Day 15 (Pre-CAE)-7.8 ± 23.00-1.3 ± 18.83-5.0 ± 17.15
Change from Baseline: Day 15 (Post-CAE)-8.5 ± 20.45-0.7 ± 21.90-7.9 ± 18.96
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-0.6 ± 28.160.8 ± 27.76-2.8 ± 20.72
Change from Baseline: Day 29 (Pre-CAE)-6.2 ± 28.69-5.0 ± 16.97-5.9 ± 26.37
Change from Baseline: Day 29 (Post-CAE)-8.6 ± 16.41-4.7 ± 19.58-1.1 ± 20.54
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)1.4 ± 19.182.6 ± 19.77-0.6 ± 22.53
Change from Baseline: Day 57 (Pre-CAE)-9.3 ± 21.64-7.3 ± 28.49-5.2 ± 18.58
Change from Baseline: Day 57 (Post-CAE)-10.3 ± 23.81-1.5 ± 27.06-8.5 ± 19.20
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-1.0 ± 27.776.9 ± 30.44-3.7 ± 25.32
SecondaryChange From Baseline in Visual Analog Scale (Blurred Vision)

Participants rated ocular symptom of blurred vision by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · mm
Change From Baseline in Visual Analog Scale (Blurred Vision)
mm0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE18.5 ± 22.8524.0 ± 27.0026.9 ± 20.32
Day 1 Post-CAE26.4 ± 28.3032.2 ± 30.8241.1 ± 28.62
Day 1 (Change from Pre-CAE to Post-CAE)7.9 ± 18.338.2 ± 25.1514.2 ± 20.98
Change from Baseline: Day 82.5 ± 12.34-4.5 ± 23.77-4.2 ± 15.37
Change from Baseline: Day 15 (Pre-CAE)3.7 ± 11.94-2.9 ± 19.40-2.1 ± 15.80
Change from Baseline: Day 15 (Post-CAE)-1.1 ± 14.37-7.3 ± 24.44-8.7 ± 21.87
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-4.7 ± 16.88-4.4 ± 23.96-6.6 ± 27.55
Change from Baseline: Day 29 (Pre-CAE)-2.0 ± 14.81-4.0 ± 18.45-3.2 ± 16.29
Change from Baseline: Day 29 (Post-CAE)-5.9 ± 16.34-7.9 ± 23.39-6.1 ± 17.73
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-2.5 ± 19.24-5.4 ± 21.62-7.7 ± 21.60
Change from Baseline: Day 57 (Pre-CAE)0.5 ± 14.90-3.0 ± 21.79-1.2 ± 19.67
Change from Baseline: Day 57 (Post-CAE)-4.0 ± 19.15-6.9 ± 24.83-7.8 ± 21.29
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-4.5 ± 17.82-3.3 ± 27.89-6.5 ± 27.14
SecondaryChange From Baseline in Visual Analog Scale (Dryness)

Participants rated ocular symptom of dryness by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · mm
Change From Baseline in Visual Analog Scale (Dryness)
mm0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE57.7 ± 20.9858.6 ± 24.5858.0 ± 22.90
Day 1 Post-CAE74.2 ± 18.6671.8 ± 21.4775.0 ± 18.09
Day 1 (Change from Pre-CAE to Post-CAE)16.5 ± 16.7613.3 ± 17.8017.0 ± 18.30
Change from Baseline: Day 8-4.7 ± 16.31-2.1 ± 14.26-1.6 ± 19.15
Change from Baseline: Day 15 (Pre-CAE)-6.7 ± 19.32-7.4 ± 17.94-4.2 ± 20.52
Change from Baseline: Day 15 (Post-CAE)-1.7 ± 12.82-4.5 ± 16.69-1.7 ± 17.81
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)5.0 ± 21.303.0 ± 21.222.5 ± 22.67
Change from Baseline: Day 29 (Pre-CAE)-6.4 ± 23.40-10.3 ± 19.89-7.1 ± 25.61
Change from Baseline: Day 29 (Post-CAE)-5.8 ± 14.15-7.1 ± 13.36-5.1 ± 12.50
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)2.3 ± 21.343.5 ± 20.860.6 ± 23.70
Change from Baseline: Day 57 (Pre-CAE)-11.7 ± 24.14-11.3 ± 26.02-8.4 ± 26.81
Change from Baseline: Day 57 (Post-CAE)-8.3 ± 15.28-3.8 ± 14.57-7.7 ± 22.21
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)3.3 ± 25.719.0 ± 24.831.7 ± 25.52
SecondaryChange From Baseline in Visual Analog Scale (Photophobia)

Participants rated ocular symptom of photophobia by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · mm
Change From Baseline in Visual Analog Scale (Photophobia)
mm0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE32.8 ± 28.4137.4 ± 33.8636.7 ± 29.19
Day 1 Post-CAE38.1 ± 29.8039.8 ± 34.5049.7 ± 32.33
Day 1 (Change from Pre-CAE to Post-CAE)5.3 ± 16.702.2 ± 21.2013.0 ± 22.01
Change from Baseline: Day 81.4 ± 16.17-5.0 ± 21.40-2.7 ± 18.46
Change from Baseline: Day 15 (Pre-CAE)-1.4 ± 16.19-11.0 ± 22.36-2.1 ± 18.17
Change from Baseline: Day 15 (Post-CAE)-2.4 ± 14.21-5.7 ± 19.94-8.8 ± 18.47
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-1.0 ± 19.595.8 ± 23.32-6.7 ± 22.12
Change from Baseline: Day 29 (Pre-CAE)-3.1 ± 19.61-7.3 ± 28.18-3.1 ± 26.01
Change from Baseline: Day 29 (Post-CAE)-4.0 ± 13.84-4.9 ± 18.11-0.9 ± 18.18
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)3.0 ± 17.382.1 ± 13.89-2.7 ± 27.46
Change from Baseline: Day 57 (Pre-CAE)-4.1 ± 20.87-3.6 ± 26.95-3.6 ± 22.33
Change from Baseline: Day 57 (Post-CAE)-4.0 ± 21.66-2.3 ± 20.85-10.4 ± 23.91
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)0.2 ± 28.341.5 ± 21.40-6.5 ± 24.53
SecondaryChange From Baseline in Visual Analog Scale (Pain)

Participants rated ocular symptom of pain by placing a vertical mark on the horizontal line to indicate the level of discomfort. 0 mm corresponds to "no discomfort" and 100 mm corresponds to "maximal discomfort."

Time frame:
Baseline (Day 1 Pre-CAE and Post-CAE), Day 8, Day 15 (Pre-CAE and Post-CAE), Day 29 (Pre-CAE and Post-CAE), and Day 57 (Pre-CAE and Post-CAE)
Reported as:
Mean · mm
Change From Baseline in Visual Analog Scale (Pain)
mm0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 1 Pre-CAE17.0 ± 22.3117.8 ± 23.6217.4 ± 21.01
Day 1 Post-CAE29.1 ± 30.5026.3 ± 29.5327.1 ± 29.83
Day 1 (Change from Pre-CAE to Post-CAE)12.1 ± 19.658.3 ± 15.819.7 ± 20.73
Change from Baseline: Day 8-2.2 ± 11.94-1.8 ± 22.41-2.6 ± 13.91
Change from Baseline: Day 15 (Pre-CAE)1.8 ± 20.34-3.1 ± 22.90-2.1 ± 14.54
Change from Baseline: Day 15 (Post-CAE)-3.9 ± 17.59-2.0 ± 16.84-2.8 ± 18.66
Change from baseline: Day 15 (Change from Pre-CAE to Post-CAE)-5.7 ± 19.811.5 ± 22.96-0.8 ± 23.07
Change from Baseline: Day 29 (Pre-CAE)-3.8 ± 17.30-3.3 ± 20.23-3.4 ± 15.35
Change from Baseline: Day 29 (Post-CAE)-8.0 ± 16.05-1.8 ± 18.57-9.9 ± 18.61
Change from baseline: Day 29 (Change from Pre-CAE to Post-CAE)-3.3 ± 15.387.7 ± 16.05-8.1 ± 20.05
Change from Baseline: Day 57 (Pre-CAE)-0.2 ± 22.85-6.6 ± 24.80-2.8 ± 14.32
Change from Baseline: Day 57 (Post-CAE)-10.9 ± 16.16-4.1 ± 20.22-2.1 ± 12.68
Change from baseline: Day 57 (Change from Pre-CAE to Post-CAE)-10.7 ± 28.153.9 ± 21.670.7 ± 16.52
SecondaryChange From Baseline in Ocular Surface and Disease Index (OSDI©)

The OSDI is a simple 12-question survey that rates the severity of the participant's dry eye disease based on the symptoms. It is assessed on a scale of 0 to 100, with higher score representing greater disability.

Time frame:
Baseline (Day 1); Days 8, 15, 29, and 57
Reported as:
Mean · score on a scale
Change From Baseline in Ocular Surface and Disease Index (OSDI©)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Day 132.45 ± 14.37936.78 ± 18.20938.08 ± 16.602
Change From Baseline: Day 8-1.57 ± 7.885-0.87 ± 7.889-3.79 ± 8.161
Change From Baseline: Day 15-0.49 ± 9.048-2.98 ± 10.361-3.65 ± 10.727
Change From Baseline: Day 29-0.92 ± 10.324-4.42 ± 12.540-5.48 ± 12.471
Change From Baseline: Day 57-1.45 ± 11.598-3.33 ± 11.978-5.05 ± 10.817
SecondaryOra Calibra® Drop Comfort Scale

Ora Calibra® drop comfort scale ranges from 0 to 10. A score of 0 indicates comfortable and 10 indicates uncomfortable. Lower score indicated better comfort level.

Time frame:
Upon instillation and 1 and 2 minutes post-instillation on Day 1
Reported as:
Mean · score on a scale
Ora Calibra® Drop Comfort Scale
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Upon instillation on Day 12.8 ± 2.253.6 ± 2.403.3 ± 2.69
1 minute post-instillation on Day 12.0 ± 1.862.6 ± 1.932.3 ± 1.84
2 minutes post-instillation on Day 11.6 ± 1.752.3 ± 1.912.0 ± 1.89
SecondaryDaily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of overall ocular discomfort twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Time frame:
From Baseline (Day 1) to Day 56
Reported as:
Mean · score on a scale
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Overall Ocular Discomfort)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Baseline: Daily average2.74 ± 0.8842.82 ± 0.9342.66 ± 0.789
Average Day 1 to Day 7: Change from Baseline Daily Average-0.13 ± 0.326-0.09 ± 0.337-0.07 ± 0.376
Average Day 8 to Day 14: Change from Baseline Daily Average-0.24 ± 0.430-0.10 ± 0.442-0.09 ± 0.510
Average Day 15 to Day 21: Change from Baseline Daily Average-0.21 ± 0.534-0.19 ± 0.465-0.13 ± 0.628
Average Day 22 to Day 28: Change from Baseline Daily Average-0.23 ± 0.558-0.29 ± 0.464-0.24 ± 0.650
Average Day 29 to Day 35: Change from Baseline Daily Average-0.18 ± 0.600-0.25 ± 0.548-0.15 ± 0.623
Average Day 36 to Day 42: Change from Baseline Daily Average-0.28 ± 0.597-0.28 ± 0.638-0.18 ± 0.638
Average Day 43 to Day 49: Change from Baseline Daily Average-0.34 ± 0.636-0.31 ± 0.666-0.16 ± 0.662
Average Day 50 to Day 56: Change from Baseline Daily Average-0.38 ± 0.713-0.29 ± 0.658-0.16 ± 0.674
SecondaryDaily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of burning twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Time frame:
From Baseline (Day 1) to Day 56
Reported as:
Mean · score on a scale
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Burning)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Baseline: Daily average1.72 ± 1.1261.49 ± 1.1341.50 ± 1.135
Average Day 1 to Day 7: Change from Baseline Daily Average-0.13 ± 0.309-0.08 ± 0.398-0.07 ± 0.328
Average Day 8 to Day 14: Change from Baseline Daily Average-0.26 ± 0.369-0.17 ± 0.438-0.11 ± 0.420
Average Day 15 to Day 21: Change from Baseline Daily Average-0.22 ± 0.430-0.21 ± 0.498-0.12 ± 0.464
Average Day 22 to Day 28: Change from Baseline Daily Average-0.26 ± 0.449-0.29 ± 0.511-0.18 ± 0.546
Average Day 29 to Day 35: Change from Baseline Daily Average-0.18 ± 0.506-0.28 ± 0.523-0.11 ± 0.511
Average Day 36 to Day 42: Change from Baseline Daily Average-0.25 ± 0.440-0.35 ± 0.701-0.17 ± 0.500
Average Day 43 to Day 49: Change from Baseline Daily Average-0.25 ± 0.565-0.33 ± 0.647-0.13 ± 0.564
Average Day 50 to Day 56: Change from Baseline Daily Average-0.27 ± 0.571-0.33 ± 0.739-0.11 ± 0.527
SecondaryDaily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of dryness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Time frame:
From Baseline (Day 1) to Day 56
Reported as:
Mean · score on a scale
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Dryness)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Baseline: Daily average2.88 ± 0.7932.96 ± 0.9682.99 ± 0.669
Average Day 1 to Day 7: Change from Baseline Daily Average-0.13 ± 0.391-0.11 ± 0.275-0.10 ± 0.383
Average Day 8 to Day 14: Change from Baseline Daily Average-0.20 ± 0.505-0.14 ± 0.388-0.13 ± 0.504
Average Day 15 to Day 21: Change from Baseline Daily Average-0.20 ± 0.615-0.25 ± 0.479-0.13 ± 0.621
Average Day 22 to Day 28: Change from Baseline Daily Average-0.23 ± 0.620-0.30 ± 0.519-0.29 ± 0.659
Average Day 29 to Day 35: Change from Baseline Daily Average-0.17 ± 0.691-0.29 ± 0.485-0.21 ± 0.690
Average Day 36 to Day 42: Change from Baseline Daily Average-0.30 ± 0.680-0.32 ± 0.628-0.23 ± 0.677
Average Day 43 to Day 49: Change from Baseline Daily Average-0.35 ± 0.728-0.31 ± 0.704-0.25 ± 0.768
Average Day 50 to Day 56: Change from Baseline Daily Average-0.40 ± 0.793-0.29 ± 0.703-0.27 ± 0.812
SecondaryDaily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of grittiness twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Time frame:
From Baseline (Day 1) to Day 56
Reported as:
Mean · score on a scale
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Grittiness)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Baseline: Daily average2.14 ± 0.9881.84 ± 1.2482.07 ± 1.177
Average Day 1 to Day 7: Change from Baseline Daily Average-0.19 ± 0.450-0.07 ± 0.331-0.03 ± 0.407
Average Day 8 to Day 14: Change from Baseline Daily Average-0.27 ± 0.555-0.07 ± 0.500-0.08 ± 0.555
Average Day 15 to Day 21: Change from Baseline Daily Average-0.22 ± 0.594-0.16 ± 0.540-0.14 ± 0.554
Average Day 22 to Day 28: Change from Baseline Daily Average-0.26 ± 0.628-0.21 ± 0.615-0.23 ± 0.655
Average Day 29 to Day 35: Change from Baseline Daily Average-0.21 ± 0.724-0.22 ± 0.554-0.18 ± 0.627
Average Day 36 to Day 42: Change from Baseline Daily Average-0.35 ± 0.682-0.18 ± 0.642-0.18 ± 0.561
Average Day 43 to Day 49: Change from Baseline Daily Average-0.38 ± 0.682-0.16 ± 0.833-0.16 ± 0.666
Average Day 50 to Day 56: Change from Baseline Daily Average-0.36 ± 0.764-0.11 ± 0.959-0.18 ± 0.708
SecondaryDaily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)

Ora Calibra® ocular discomfort \& 4-symptom questionnaire for dry eye includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Participants rated the severity of stinging twice a day in a diary on 0 to 5 scale, where 0=none and 5=severe. Higher score represent higher severity. The average of the morning and evening assessments were calculated for each day. Weekly average scores were calculated based on the daily scores in the week.

Time frame:
From Baseline (Day 1) to Day 56
Reported as:
Mean · score on a scale
Daily Diary: Change From Baseline in Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire for Dry Eye (Stinging)
score on a scale0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
Baseline: Daily average1.53 ± 1.1131.20 ± 1.1271.26 ± 1.075
Average Day 1 to Day 7: Change from Baseline Daily Average-0.14 ± 0.349-0.13 ± 0.327-0.11 ± 0.342
Average Day 8 to Day 14: Change from Baseline Daily Average-0.24 ± 0.409-0.12 ± 0.438-0.14 ± 0.469
Average Day 15 to Day 21: Change from Baseline Daily Average-0.16 ± 0.428-0.22 ± 0.515-0.20 ± 0.455
Average Day 22 to Day 28: Change from Baseline Daily Average-0.12 ± 0.517-0.28 ± 0.533-0.24 ± 0.546
Average Day 29 to Day 35: Change from Baseline Daily Average-0.11 ± 0.572-0.28 ± 0.538-0.21 ± 0.517
Average Day 36 to Day 42: Change from Baseline Daily Average-0.22 ± 0.564-0.32 ± 0.631-0.20 ± 0.514
Average Day 43 to Day 49: Change from Baseline Daily Average-0.24 ± 0.553-0.27 ± 0.647-0.16 ± 0.612
Average Day 50 to Day 56: Change from Baseline Daily Average-0.22 ± 0.575-0.28 ± 0.744-0.15 ± 0.577

Adverse events

Collected over Baseline up to 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.10% HL036 Ophthalmic Solution0/50 (0%)0/50 (0%)13/50 (26%)
0.25% HL036 Ophthalmic Solution0/50 (0%)0/50 (0%)13/50 (26%)
Placebo0/50 (0%)0/50 (0%)9/50 (18%)
Most frequent other events
Most frequent other events
Event0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlacebo
NasopharyngitisInfections and infestations5/503/508/50
Instillation site painGeneral disorders2/506/501/50
Conjunctivitis allergicEye disorders3/504/500/50
Visual acuity reducedEye disorders3/500/500/50

Baseline characteristics

Intent-to-treat (ITT) population: The ITT population included all randomized participants.

Age, Continuous
Age, Continuous(years)0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlaceboTotal
Mean60.9 ± 13.0963.5 ± 9.9266.1 ± 11.3863.5 ± 11.65
Sex: Female, Male
Sex: Female, Male(Participants)0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlaceboTotal
Female304038108
Male20101242
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlaceboTotal
Hispanic or Latino2125
Not Hispanic or Latino484948145
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0.10% HL036 Ophthalmic Solution0.25% HL036 Ophthalmic SolutionPlaceboTotal
American Indian or Alaska Native1001
Asian0112
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White494848145
More than one race0101
Unknown or Not Reported0000
08

Study locations

2 sites
  • Central Maine Eye Care
    Lewiston, Maine 04240, United States
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Apr 2018, 5 months.

Results were first posted in Jan 2022, 3 years 9 months after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 5 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2017
First posted
Nov 7, 2017
StartActual
Nov 5, 2017
Primary completionActual
Apr 9, 2018
CompletionActual
Apr 9, 2018
Results first posted
Jan 26, 2022
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03334539
Responsible party
Sponsor
First posted
Nov 7, 2017
Start date
Nov 5, 2017
Primary completion
Apr 9, 2018
Completion
Apr 9, 2018
Results posted
Jan 26, 2022
Last update
Mar 7, 2024

Study contacts

Gail Torkildsen, MD
principal investigator · Andover Eye Associates

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tanfanercept

Start the discussion